EV/Assets Ratio: 4.40x
Is the EV/Assets ratio high or low?
The EV/Assets ratio of 4.40x is 15% below its 5-year average of 5.19x, near the low end of its 5-year range (2.70x–9.85x).
As of Saturday, June 27, 2026. 22.79% above its 12-month average of 3.58x.
TECH EV/Assets Ratio Chart
TECH Average EV/Assets Ratio Chart
TECH Current vs Average EV/Assets Ratio Chart
TECH EV/Assets Ratio Metrics
EV/ASSETS RATIO
4.40x
EV/ASSETS RATIO AVG TTM
3.58x
EV/ASSETS RATIO AVG 3Y
4.05x
EV/ASSETS RATIO AVG 5Y
4.88x
EV/ASSETS RATIO AVG 10Y
4.44x
EV/ASSETS RATIO AVG 15Y
4.01x
EV/ASSETS RATIO AVG 20Y
4.30x
CURRENT VS TTM AVG
+22.79%
CURRENT VS 3Y AVG
+8.68%
CURRENT VS 5Y AVG
-9.77%
CURRENT VS 10Y AVG
-0.92%
CURRENT VS 15Y AVG
+9.79%
CURRENT VS 20Y AVG
+2.36%
TECH Competitors' EV/Assets Ratio
| NAME | MARKET CAP | EV/ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bio-Techne Corporation (TECH) | $11.12B | 4.40x | 3.58x | 4.05x | 4.88x |
| Insulet Corp. (PODD)vs › | $10.96B | 3.88x | 5.89x | 6.05x | 7.36x |
| Baxter International Inc. (BAX)vs › | $11.38B | 0.96x | 0.90x | 1.04x | 1.31x |
| Molina Healthcare, Inc. (MOH)vs › | $11.79B | 0.59x | 0.53x | 0.93x | 1.07x |
| Charles River Laboratories International, Inc. (CRL)vs › | $10.39B | 1.74x | 1.51x | 1.59x | 1.93x |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | 0.56x | 0.52x | 0.58x | 0.69x |
| Tempus AI, Inc. (TEM)vs › | $9.80B | 5.08x | 6.17x | 7.83x | 7.83x |
| Henry Schein, Inc. (HSIC)vs › | $9.68B | 1.19x | 1.10x | 1.15x | 1.27x |
| Revvity, Inc. (RVTY)vs › | $12.61B | 1.26x | 1.11x | 1.18x | 1.38x |
| Align Technology, Inc. (ALGN)vs › | $12.78B | 1.84x | 1.75x | 2.53x | 3.70x |
EV/Assets Ratio Formula & Definition
EV/Assets compares enterprise value to total assets. It is useful for asset-heavy businesses and for comparing how much the market pays for each dollar of assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
EV/Assets Ratio FAQ
- What is the EV/Assets ratio for Bio-Techne Corporation (TECH)?
- The EV/Assets ratio for TECH stock is 4.40x.
- Is Bio-Techne Corporation's EV/Assets ratio high or low?
- The EV/Assets ratio of 4.40x is 15% below its 5-year average of 5.19x, near the low end of its 5-year range (2.70x–9.85x).
- What is the TTM average EV/Assets ratio for Bio-Techne Corporation (TECH)?
- The TTM average EV/Assets ratio for TECH stock is 3.58x.
- What is the 3Y average EV/Assets ratio for Bio-Techne Corporation (TECH)?
- The 3Y average EV/Assets ratio for TECH stock is 4.05x.
- What is the 5Y average EV/Assets ratio for Bio-Techne Corporation (TECH)?
- The 5Y average EV/Assets ratio for TECH stock is 4.88x.
- What is the 10Y average EV/Assets ratio for Bio-Techne Corporation (TECH)?
- The 10Y average EV/Assets ratio for TECH stock is 4.44x.
- What is the 15Y average EV/Assets ratio for Bio-Techne Corporation (TECH)?
- The 15Y average EV/Assets ratio for TECH stock is 4.01x.
- What is the 20Y average EV/Assets ratio for Bio-Techne Corporation (TECH)?
- The 20Y average EV/Assets ratio for TECH stock is 4.30x.
TECH EV/Assets Ratio History
| DATE | EV/ASSETS RATIO |
|---|---|
| 2026-06-26 | 4.40x |
| 2026-06-25 | 4.38x |
| 2026-06-24 | 3.65x |
| 2026-06-23 | 3.49x |
| 2026-06-22 | 3.45x |
| 2026-06-18 | 3.60x |
| 2026-06-17 | 3.42x |
| 2026-06-16 | 3.48x |
| 2026-06-15 | 3.49x |
| 2026-06-12 | 3.35x |
| 2026-06-11 | 3.36x |
| 2026-06-10 | 3.26x |
| 2026-06-09 | 3.38x |
| 2026-06-08 | 3.27x |
| 2026-06-05 | 3.23x |
| 2026-06-04 | 3.30x |
| 2026-06-03 | 3.16x |
| 2026-06-02 | 3.09x |
| 2026-06-01 | 3.16x |
| 2026-05-29 | 3.21x |
| 2026-05-28 | 3.16x |
| 2026-05-27 | 2.99x |
| 2026-05-26 | 2.98x |
| 2026-05-22 | 3.00x |
| 2026-05-21 | 2.95x |
| 2026-05-20 | 2.91x |
| 2026-05-19 | 2.83x |
| 2026-05-18 | 2.77x |
| 2026-05-15 | 2.70x |
| 2026-05-14 | 2.78x |
| 2026-05-13 | 2.79x |
| 2026-05-12 | 2.95x |
| 2026-05-11 | 2.95x |
| 2026-05-08 | 3.01x |
| 2026-05-07 | 3.16x |
| 2026-05-06 | 2.95x |
| 2026-05-05 | 3.60x |
| 2026-05-04 | 3.48x |
| 2026-05-01 | 3.49x |
| 2026-04-30 | 3.51x |
| 2026-04-29 | 3.30x |
| 2026-04-28 | 3.40x |
| 2026-04-27 | 3.50x |
| 2026-04-24 | 3.44x |
| 2026-04-23 | 3.32x |
| 2026-04-22 | 3.72x |
| 2026-04-21 | 3.78x |
| 2026-04-20 | 3.84x |
| 2026-04-17 | 3.76x |
| 2026-04-16 | 3.64x |
| 2026-04-15 | 3.71x |
| 2026-04-14 | 3.72x |
| 2026-04-13 | 3.65x |
| 2026-04-10 | 3.53x |
| 2026-04-09 | 3.53x |
| 2026-04-08 | 3.51x |
| 2026-04-07 | 3.42x |
| 2026-04-06 | 3.42x |
| 2026-04-02 | 3.38x |
| 2026-04-01 | 3.40x |
| 2026-03-31 | 3.32x |
| 2026-03-30 | 3.31x |
| 2026-03-27 | 3.24x |
| 2026-03-26 | 3.35x |
| 2026-03-25 | 3.35x |
| 2026-03-24 | 3.33x |
| 2026-03-23 | 3.31x |
| 2026-03-20 | 3.27x |
| 2026-03-19 | 3.28x |
| 2026-03-18 | 3.23x |
| 2026-03-17 | 3.25x |
| 2026-03-16 | 3.11x |
| 2026-03-13 | 3.24x |
| 2026-03-12 | 3.27x |
| 2026-03-11 | 3.41x |
| 2026-03-10 | 3.36x |
| 2026-03-09 | 3.49x |
| 2026-03-06 | 3.42x |
| 2026-03-05 | 3.55x |
| 2026-03-04 | 3.67x |
| 2026-03-03 | 3.62x |
| 2026-03-02 | 3.67x |
| 2026-02-27 | 3.74x |
| 2026-02-26 | 3.68x |
| 2026-02-25 | 3.67x |
| 2026-02-24 | 3.66x |
| 2026-02-23 | 3.48x |
| 2026-02-20 | 3.65x |
| 2026-02-19 | 3.70x |
| 2026-02-18 | 3.76x |
| 2026-02-17 | 3.71x |
| 2026-02-13 | 3.80x |
| 2026-02-12 | 3.78x |
| 2026-02-11 | 4.02x |
| 2026-02-10 | 4.10x |
| 2026-02-09 | 4.15x |
| 2026-02-06 | 4.23x |
| 2026-02-05 | 4.17x |
| 2026-02-04 | 4.34x |
| 2026-02-03 | 4.10x |
| 2026-02-02 | 4.14x |
| 2026-01-30 | 4.07x |
| 2026-01-29 | 4.06x |
| 2026-01-28 | 4.16x |
| 2026-01-27 | 4.32x |
| 2026-01-26 | 4.28x |
| 2026-01-23 | 4.32x |
| 2026-01-22 | 4.41x |
| 2026-01-21 | 4.52x |
| 2026-01-20 | 4.40x |
| 2026-01-16 | 4.35x |
| 2026-01-15 | 4.43x |
| 2026-01-14 | 4.33x |
| 2026-01-13 | 4.21x |
| 2026-01-12 | 4.22x |
| 2026-01-09 | 4.17x |
| 2026-01-08 | 4.10x |
| 2026-01-07 | 4.13x |
| 2026-01-06 | 4.14x |
| 2026-01-05 | 4.00x |
| 2026-01-02 | 3.79x |
| 2025-12-31 | 3.74x |
| 2025-12-30 | 3.76x |
| 2025-12-29 | 3.77x |
| 2025-12-26 | 3.76x |
| 2025-12-24 | 3.76x |
| 2025-12-23 | 3.77x |
| 2025-12-22 | 3.75x |
| 2025-12-19 | 3.71x |
| 2025-12-18 | 3.63x |
| 2025-12-17 | 3.63x |
| 2025-12-16 | 3.65x |
| 2025-12-15 | 3.73x |
| 2025-12-12 | 3.72x |
| 2025-12-11 | 3.83x |
| 2025-12-10 | 3.86x |
| 2025-12-09 | 3.74x |
| 2025-12-08 | 3.83x |
| 2025-12-05 | 3.92x |
| 2025-12-04 | 4.03x |
| 2025-12-03 | 4.05x |
| 2025-12-02 | 4.00x |
| 2025-12-01 | 4.05x |
| 2025-11-28 | 4.09x |
| 2025-11-26 | 4.10x |
| 2025-11-25 | 4.17x |
| 2025-11-24 | 4.03x |
| 2025-11-21 | 3.91x |
| 2025-11-20 | 3.73x |
| 2025-11-19 | 3.68x |
| 2025-11-18 | 3.70x |
| 2025-11-17 | 3.73x |
| 2025-11-14 | 3.77x |
| 2025-11-13 | 3.86x |
| 2025-11-12 | 3.90x |
| 2025-11-11 | 3.76x |
| 2025-11-10 | 3.66x |
| 2025-11-07 | 3.65x |
| 2025-11-06 | 3.70x |
| 2025-11-05 | 3.81x |
| 2025-11-04 | 3.83x |
| 2025-11-03 | 3.84x |
| 2025-10-31 | 3.92x |
| 2025-10-30 | 3.82x |
| 2025-10-29 | 3.89x |
| 2025-10-28 | 4.00x |
| 2025-10-27 | 4.02x |
| 2025-10-24 | 4.12x |
| 2025-10-23 | 4.13x |
| 2025-10-22 | 3.99x |
| 2025-10-21 | 3.97x |
| 2025-10-20 | 3.92x |
| 2025-10-17 | 3.88x |
| 2025-10-16 | 3.86x |
| 2025-10-15 | 3.74x |
| 2025-10-14 | 3.72x |
| 2025-10-13 | 3.74x |
| 2025-10-10 | 3.68x |
| 2025-10-09 | 3.76x |
| 2025-10-08 | 3.80x |
| 2025-10-07 | 3.71x |
| 2025-10-06 | 3.88x |
| 2025-10-03 | 3.94x |
| 2025-10-02 | 3.89x |
| 2025-10-01 | 3.76x |
| 2025-09-30 | 3.50x |
| 2025-09-29 | 3.29x |
| 2025-09-26 | 3.27x |
| 2025-09-25 | 3.18x |
| 2025-09-24 | 3.23x |
| 2025-09-23 | 3.33x |
| 2025-09-22 | 3.34x |
| 2025-09-19 | 3.35x |
| 2025-09-18 | 3.34x |
| 2025-09-17 | 3.25x |
| 2025-09-16 | 3.26x |
| 2025-09-15 | 3.25x |
| 2025-09-12 | 3.23x |
| 2025-09-11 | 3.35x |
| 2025-09-10 | 3.21x |
| 2025-09-09 | 3.41x |
| 2025-09-08 | 3.41x |
| 2025-09-05 | 3.42x |
| 2025-09-04 | 3.33x |
| 2025-09-03 | 3.36x |
| 2025-09-02 | 3.36x |
| 2025-08-29 | 3.44x |
| 2025-08-28 | 3.42x |
| 2025-08-27 | 3.53x |
| 2025-08-26 | 3.57x |
| 2025-08-25 | 3.56x |
| 2025-08-22 | 3.59x |
| 2025-08-21 | 3.35x |
| 2025-08-20 | 3.37x |
| 2025-08-19 | 3.41x |
| 2025-08-18 | 3.31x |
| 2025-08-15 | 3.33x |
| 2025-08-14 | 3.34x |
| 2025-08-13 | 3.40x |
| 2025-08-12 | 3.28x |
| 2025-08-11 | 3.12x |
| 2025-08-08 | 3.14x |
| 2025-08-07 | 3.12x |
| 2025-08-06 | 3.10x |
| 2025-08-05 | 3.39x |
| 2025-08-04 | 3.41x |
| 2025-08-01 | 3.41x |
| 2025-07-31 | 3.40x |
| 2025-07-30 | 3.58x |
| 2025-07-29 | 3.59x |
| 2025-07-28 | 3.63x |
| 2025-07-25 | 3.64x |
| 2025-07-24 | 3.62x |
| 2025-07-23 | 3.43x |
| 2025-07-22 | 3.30x |
| 2025-07-21 | 3.13x |
| 2025-07-18 | 3.23x |
| 2025-07-17 | 3.31x |
| 2025-07-16 | 3.22x |
| 2025-07-15 | 3.20x |
| 2025-07-14 | 3.27x |
| 2025-07-11 | 3.36x |
| 2025-07-10 | 3.38x |
| 2025-07-09 | 3.27x |
| 2025-07-08 | 3.27x |
| 2025-07-07 | 3.20x |
| 2025-07-03 | 3.30x |
| 2025-07-02 | 3.30x |
| 2025-07-01 | 3.24x |
| 2025-06-30 | 3.20x |
| 2025-06-27 | 3.22x |
| 2025-06-26 | 3.28x |
| 2025-06-25 | 3.23x |
| 2025-06-24 | 3.11x |
| 2025-06-23 | 3.07x |
| 2025-06-20 | 3.11x |
| 2025-06-18 | 3.12x |
| 2025-06-17 | 3.08x |
| 2025-06-16 | 3.21x |
| 2025-06-13 | 3.14x |
Showing the most recent 260 of 5,032 data points. The chart above shows the full history.
Related Metrics
About Bio-Techne Corporation
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Kim Kelderman